Drug Trial Radar · NCT04494425
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
866
Actual
Start
Jul 24, 2020
Primary completion
Mar 18, 2024
Study completion Jun 19, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Jul 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 105 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
Conditions
- Advanced or Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecanDrug
Trastuzumab deruxtecan by intravenous infusion
CapecitabineDrug
Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
PaclitaxelDrug
Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.
Nab-PaclitaxelDrug
Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low PopulationTime frame: Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Locations
293 sites in 28 countries. Site status is shown where the registry gives one.
Research Site
Scottsdale, Arizona
Research Site
Springdale, Arkansas
Research Site
Duarte, California
Research Site
Los Angeles, California
Research Site
Aurora, Colorado
Research Site
Lakewood, Colorado
Research Site
Washington D.C., District of Columbia
Research Site
Jacksonville, Florida
Research Site
Kansas City, Kansas
Research Site
Louisville, Kentucky
Research Site
Bethesda, Maryland
Research Site
Boston, Massachusetts
Research Site
Detroit, Michigan
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
Summit, New Jersey
Research Site
Westbury, New York
Research Site
Columbus, Ohio
Research Site
Pittsburgh, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Houston, Texas
Research Site
Norfolk, Virginia
Research Site
Seattle, Washington
Research Site
Madison, Wisconsin
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
La Plata, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Rosario, Argentina
Research Site
Adelaide, Australia
Research Site
Birtinya, Australia
Research Site
Darlinghurst, Australia
Showing 40 of 293 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.